NKTX — Nkarta, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787400 ·
Last close
$2.59
Market Cap
$185.51M
52W High
$3.72
52W Low
$2.05
ADV30
614,163
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -30,876,000 | -27,832,000 | 372,073,000 | 27,356,000 | 86,213,000 |
| Dec 2025 | 0 | — | -30,961,000 | -27,409,000 | 404,209,000 | 39,634,000 | 91,884,000 |
| Sep 2025 | 0 | — | -27,286,000 | -21,715,000 | 427,236,000 | 60,114,000 | 89,336,000 |
| Jun 2025 | 0 | — | -27,186,000 | -22,977,000 | 448,312,000 | 53,414,000 | 90,644,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,286,000
Investing CF
$61,897,000
Financing CF
$147,000
CapEx
$-1,629,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.34
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-676,140,000
Inventory
—
Receivables
—
ST Investments
$203,072,000
EBIT TTM
$-116,309,000
Pretax Income TTM
$-99,933,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -121,997,000 | -104,084,000 | 404,209,000 | 91,884,000 | — | -88,699,000 |
| Dec 2024 | 0 | -128,194,000 | -108,790,000 | 501,203,000 | 93,227,000 | — | -99,696,000 |
| Dec 2023 | 0 | -131,650,000 | -117,501,000 | 378,885,000 | 105,600,000 | — | -86,160,000 |
| Dec 2022 | 0 | -118,955,000 | -113,837,000 | 472,938,000 | 100,731,000 | — | -57,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.75
Max Pain — expiry 2026-11-20
max pain strike: $2.50 · spot: $2.59 · call oi: 3,281 · put oi: 132
Expected Move to 2026-11-20:
±$1.10
(42.47%) —
implied range
$1.49 –
$3.69
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $178.86M | $1.68 | — |
| KRRO | Korro Bio, Inc. | $192.46M | $13.07 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $177.67M | $1.26 | — |
| DERM | Journey Medical Corp | $175.79M | $7.91 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $197.26M | $4.82 | — |
News headlines (Yahoo Finance, 1h cache)
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
2026-08-10 20:24 · Yahoo
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-26 12:45 · Yahoo
Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
2026-05-14 11:12 · Yahoo
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-12 20:01 · Yahoo
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
2026-04-15 20:01 · Yahoo
Nkarta to Participate in Needham Virtual Healthcare Conference
2026-04-09 11:00 · Yahoo
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
2026-07-23 05:30 · Yahoo
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
2026-04-17 14:28 · Yahoo
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
2026-03-25 20:01 · Yahoo
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
2026-03-10 21:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.